Related Experiment Videos
Predictors of cardiac sarcoidosis using commonly available cardiac studies
Andrew M Freeman1, Douglas Curran-Everett, Howard D Weinberger
1Division of Cardiology, Sarcoidosis Program, Department of Medicine, National Jewish Health, Denver, Colorado, USA. freemana@njhealth.org
Insights
A new scoring system using common clinical tests helps predict cardiac sarcoidosis findings on imaging. This tool aids in diagnosing the condition, which significantly impacts patient mortality.
Area of Science:
- Cardiology
- Immunology
- Radiology
Background:
- Cardiac sarcoidosis affects up to 40% of sarcoidosis patients, contributing to 25% of deaths.
- Diagnosing cardiac sarcoidosis is challenging, often requiring expensive imaging like cardiac magnetic resonance imaging (cMRI) and 18-fluorodeoxyglucose positron emission tomography (FDG-cPET).
Purpose of the Study:
- To develop and validate a scoring system using common clinical tests to predict positive findings on cMRI or FDG-cPET for diagnosing cardiac sarcoidosis.
- To assess the predictive ability of a composite score derived from standard clinical assessments.
Main Methods:
- Retrospective chart review of patients who underwent cMRI or FDG-cPET for suspected cardiac sarcoidosis.
- Data extraction and scoring using a predetermined system based on common clinical tests.
- Comparison of the developed scoring system against cMRI and FDG-cPET findings.
Main Results:
- A 1-point increase in the total score correlated with a 14% increased probability of positive cMRI or FDG-cPET findings (p=0.01).
- Positive findings from a single imaging study were as predictive as results from both.
- The scoring system appeared more influenced by cMRI findings than FDG-cPET findings.
Conclusions:
- A composite scoring system using common cardiac screening tools shows promise in predicting positive imaging findings for cardiac sarcoidosis.
- While the system requires refinement, major findings from screening studies are more predictive of cMRI results.
- The developed scoring system offers a potentially more accessible approach to identifying patients likely to have cardiac sarcoidosis.
Abstract:
Cardiac involvement affects ≤40% of patients with sarcoidosis and accounts for ≤25% of deaths. The diagnosis of cardiac sarcoidosis is challenging using the existing screening tests and often relies on expensive cardiac magnetic resonance imaging (cMRI) and cardiac 18-fluorodeoxuyglucose positron emission tomography (FDG-cPET). We developed a scoring system using common clinical tests to predict positive imaging findings using cMRI or FDG-cPET. A retrospective chart review of subjects undergoing cMRI or FDG-cPET was performed. The data were extracted and scored using a predetermined system. Our cohort was predominantly white, with a mean age of 55 years, and 60% were women. The scoring system was compared with the findings from cMRI and FDG-cPET to determine the ability to predict the imaging results that define cardiac sarcoidosis. The scoring system for the patients who had undergone both FDG-cPET and cMRI suggested predictability, but the differences were not statistically significant. However, the positive results from just 1 study were as predictive as having positive findings from both studies. A 1-point increase in the total score increased the probability of positive findings from cMRI or FDG-cPET by 14% (95% confidence interval 3% to 25% increase; p = 0.01). The scoring system seemed to be driven more by the findings from cMRI than by those from FDG-cPET. In patients who had undergone cMRI alone, for each 1-point increase in the total score, the probability of positive cMRI findings increased 11% (95% confidence interval 1% decrease to 25% increase, p = 0.08). All screening modalities were analyzed. No modality was sensitive or specific, although major findings (defined in our scoring system) were most predictive of positive imaging findings. In conclusion, commonly available cardiac screening tools used together in a composite score provide reasonable results to predict positive cardiac sarcoidosis findings on imaging, but the system needs refinement. Our data suggest that major findings from screening studies are more likely to correlate with cMRI findings than with findings from FDG-cPET.
Related Concept Videos
Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
Rheumatic Heart Disease II: Clinical Manifestations and Diagnostic Studies
Cardiomyopathy IV: Restrictive Cardiomyopathy
Acute Coronary Syndrome III: Diagnostic Studies
Imaging Studies for Cardiovascular System III: X-Ray
Definition and Purpose
An X-ray, or radiograph, is a non-invasive method that uses ionizing radiation to take images of internal structures. It is mainly used in cardiac imaging to examine the heart, lungs, and major blood vessels, aiming to identify abnormalities in the heart's size, shape, and position, such as heart failure, congenital defects, and vascular...
Blood Studies for Cardiovascular System I: Cardiac Biomarkers
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...